DSCSA’s Next Big Hurdle

News
Article
Pharmaceutical TechnologyPharmaceutical Technology, Regulatory Sourcebook, March 2022
Volume 2022 eBook
Issue 1
Pages: 40-44

Interoperability by 2023 depends on data standardization and systems compatibility between trading partners.

PETERSCHREIBER.MEDIA - STOCK.ADOBE.COM

PETERSCHREIBER.MEDIA - STOCK.ADOBE.COM

The 2023 final deadline for full US FDA Drug Supply Chain Security Act (DSCSA) unit level interoperable traceability is looming. By now, most pharmaceutical manufacturers are properly barcoding products to meet current DSCSA-specified labeling requirements for unique product identification at the lot level. The barcodes contain digitized product data that will be used to improve patient safety by enabling major improvements in the track-and-traceability of drugs as they move through the supply chain.

Now it’s time for companies to begin exchanging the necessary data to ensure readiness for November 2023. Establishing interoperability between all stakeholders up and down the supply chain is a complex undertaking—it will take every bit of time that remains before the deadline.

Read this article in Pharmaceutical Technology's March 2022 Quality and Regulatory Sourcebook eBook.

About the author

Tracy Nasarenko is senior director Community Engagement, GS1 US.

Article Details

Pharmaceutical Technology eBook: Quality and Regulatory Sourcebook, March 2022 Pages: 40-44

Citation

When referring to this article, please cite it as T. Nasarenko, “DSCSA's Next Big Hurdle," Pharmaceutical Technology Quality and Regulatory Sourcebook eBook (March 2022).

Recent Videos
Drug Digest: Strategic Partnerships
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development